{"id":40190,"date":"2022-04-27T02:23:25","date_gmt":"2022-04-27T02:23:25","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=40190"},"modified":"2026-05-05T16:13:22","modified_gmt":"2026-05-05T20:13:22","slug":"%d8%a3%d8%a8%d8%ad%d8%a7%d8%ab-%d8%b3%d9%88%d9%82-%d8%a7%d9%84%d9%85%d8%b9%d9%84%d9%88%d9%85%d8%a7%d8%aa%d9%8a%d8%a9-%d8%a7%d9%84%d8%ad%d9%8a%d9%88%d9%8a%d8%a9","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/ar\/%d8%ae%d8%a8%d8%b1%d8%a9\/%d8%a3%d8%a8%d8%ad%d8%a7%d8%ab-%d8%b3%d9%88%d9%82-%d8%a7%d9%84%d9%85%d8%b9%d9%84%d9%88%d9%85%d8%a7%d8%aa%d9%8a%d8%a9-%d8%a7%d9%84%d8%ad%d9%8a%d9%88%d9%8a%d8%a9\/","title":{"rendered":"Bioinformatics Market Research | SIS International"},"content":{"rendered":"
\n

\u0623\u0628\u062d\u0627\u062b \u0633\u0648\u0642 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a\u064a\u0629 \u0627\u0644\u062d\u064a\u0648\u064a\u0629<\/h1>\n
\"SIS<\/figure>\n<\/p>\n
\n

\u0645\u0627 \u0647\u064a \u0623\u0628\u062d\u0627\u062b \u0633\u0648\u0642 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a\u064a\u0629 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u061f<\/h2>\n

Bioinformatics deals with obtaining, storing, breaking down, and sharing biological data. It is a mix between biology and computer science. Most times, it deals with DNA as well as amino acid sequences. Further, it makes use of software programs to decide gene and protein functions. The research also brings changing<\/a> linkages into being and predicts the solid structures of proteins.<\/p>\n<\/div>\n

Bioinformatics Market Research: How Leading Life Sciences Firms Convert Sequencing Data Into Commercial Strategy<\/h1>\n

Bioinformatics has moved from a research support function to a commercial battleground. The companies winning in oncology diagnostics, multi-omics platforms, and AI-driven drug discovery are the ones treating computational biology as a market, not a tool. Bioinformatics market research is how their leadership teams size that market, segment buyers, and price against substitutes that did not exist three product cycles ago.<\/p>\n

Demand is being reshaped by three forces operating simultaneously: the collapse of per-genome sequencing costs, the migration of analysis pipelines from on-premise clusters to cloud-native architectures, and the entry of foundation models trained on protein and nucleic acid sequences. Each force changes who buys, what they buy, and what they will pay. A VP of strategy at a Fortune 500 life sciences firm needs intelligence that maps all three at once.<\/p>\n

Why Bioinformatics Market Research Requires a Different Buyer Map<\/h2>\n

The conventional approach treats bioinformatics as a software category sold to bench scientists. That model is outdated. The actual buying committee now spans translational medicine, IT infrastructure, regulatory affairs, and commercial analytics. Each function evaluates the same platform against different criteria.<\/p>\n

Translational leaders weigh pipeline reproducibility and variant-calling accuracy. IT evaluates containerization, Kubernetes orchestration, and FedRAMP or HITRUST posture. Regulatory teams scrutinize 21 CFR Part 11 audit trails and IVDR alignment for diagnostic claims. Commercial analytics scores the vendor on real-world evidence integration with claims and EHR data. A buyer map that flattens these into one persona will misprice the offer.<\/p>\n

SIS International Research has observed across B2B expert interviews with senior translational and informatics leaders that the deciding criterion in enterprise bioinformatics deals has shifted from algorithmic performance to validated interoperability with downstream regulatory and reimbursement workflows. Vendors competing on F1 score alone are losing to vendors competing on submission-ready output.<\/span><\/p>\n

The Segmentation That Drives Pricing Power<\/h2>\n

Useful bioinformatics market research segments demand by data class, not by customer size. Short-read sequencing analysis, long-read assembly, single-cell transcriptomics, spatial biology, and proteomics each carry distinct compute economics, talent scarcity, and willingness-to-pay curves. Treating them as one TAM produces strategy that wins nothing.<\/p>\n

Single-cell and spatial workflows command premium pricing because the analytical bottleneck sits with a small population of trained computational biologists. Bulk RNA-seq, by contrast, has commoditized. Illumina’s DRAGEN, NVIDIA Parabricks, and open-source nf-core pipelines have compressed margins on standard secondary analysis. The defensible revenue is moving up the stack into tertiary analysis, multi-omic integration, and clinical reporting.<\/p>\n

Geography compounds this. The European IVDR transition has reshaped vendor selection in Germany, France, and the Nordics. Chinese sequencing volume from MGI and BGI is creating a parallel bioinformatics ecosystem that does not buy Western SaaS. India is scaling clinical genomics through public-private programs that prioritize cost over feature breadth. A global TAM that ignores these is fiction.<\/p>\n

Competitive Intelligence in a Market With Three Convergent Threats<\/h2>\n

The competitive set is not what most strategy decks show. Three distinct threat vectors converge on every incumbent.<\/p>\n

The first is platform consolidation from sequencing OEMs. Illumina, Thermo Fisher, and Pacific Biosciences are bundling analysis software with instruments to capture recurring revenue and lock in workflows. The second is hyperscaler infiltration. AWS HealthOmics, Google Cloud Life Sciences, and Microsoft’s Azure Genomics are pricing infrastructure aggressively to win the data-gravity battle. The third is the AI-native entrant. Companies building on AlphaFold derivatives, ESM protein language models, and generative chemistry platforms are reframing the value proposition from analysis to discovery.<\/p>\n

In SIS International’s competitive intelligence work across genomics and computational biology, the firms expanding share are those that have repositioned their offer around a specific clinical or discovery decision rather than a horizontal toolkit. Vertical specialization in oncology variant interpretation, rare disease diagnosis, or biomarker discovery commands two to four times the contract value of generalized platforms in matched comparisons.<\/span><\/p>\n

The Voice of Customer Work That Actually Predicts Adoption<\/h2>\n

Most bioinformatics surveys ask the wrong people the wrong questions. A useful VOC program for this category combines structured B2B expert interviews with principal investigators, core facility directors, and CIOs at academic medical centers, biopharma R&D heads, and diagnostic lab medical directors. Each cohort signals different leading indicators.<\/p>\n

Core facility directors predict pipeline standardization eighteen months before it shows in revenue. Biopharma R&D heads signal where AI-augmented target identification is replacing traditional screening. Diagnostic lab directors reveal which CPT codes and reimbursement pathways are unlocking volume. Mixing these voices into one weighted insight is where bioinformatics market research earns its fee.<\/p>\n

Ethnographic observation of the analyst workflow remains underused. Watching a computational biologist switch between Galaxy, Seurat, custom Python notebooks, and a commercial platform reveals integration gaps no survey captures. These gaps are where pricing power lives.<\/p>\n

The SIS Bioinformatics Opportunity Matrix<\/h2>\n

The framework below organizes commercial opportunity by data class and decision proximity. Decision proximity measures how directly the analytical output drives a clinical, regulatory, or capital allocation decision. Higher proximity supports higher pricing and lower churn.<\/p>\n

\n\n\n\n\n\n\n\n\n\n
Data Class<\/th>\nDecision Proximity<\/th>\nCommercial Posture<\/th>\n<\/tr>\n<\/thead>\n
Bulk short-read NGS<\/td>\nLow to moderate<\/td>\nCompete on cost and throughput<\/td>\n<\/tr>\n
Single-cell and spatial<\/td>\nModerate to high<\/td>\nPremium pricing, talent-led sales<\/td>\n<\/tr>\n
Clinical variant interpretation<\/td>\nHigh<\/td>\nReimbursement-anchored, regulated<\/td>\n<\/tr>\n
Multi-omic integration for discovery<\/td>\nHigh<\/td>\nOutcome-based contracting<\/td>\n<\/tr>\n
AI-driven target and lead generation<\/td>\nVery high<\/td>\nRisk-share and milestone deals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

What Recent Engagement Patterns Reveal<\/h2>\n

Based on SIS International’s analysis of B2B engagements across diagnostics, biopharma, and instrument manufacturers, the buyers winning budget approval are reframing bioinformatics spend as either reimbursement-linked revenue or pipeline acceleration measured in months saved per program. Spend pitched as efficiency or productivity is being deferred. Spend pitched as decision velocity is being approved.<\/span><\/p>\n

This reframing changes the research brief. Sizing studies should quantify the dollar value of a six-month reduction in lead optimization or a two-week reduction in variant report turnaround. These are the numbers that move capital committees, and they are the numbers most generic syndicated reports never produce.<\/p>\n

Where the Next Cycle of Value Concentrates<\/h2>\n

Three opportunities are visible to firms running disciplined bioinformatics market research right now. Federated analysis platforms that allow multi-site clinical studies without moving patient data are winning regulatory approval in Europe and gaining traction in US academic medical center consortia. Foundation model fine-tuning services for proprietary biological data sets are creating a new professional services category. Companion diagnostic informatics, tied to specific therapeutic launches, is becoming a contractual requirement in oncology and rare disease deals.<\/p>\n

Each of these requires market sizing that does not yet exist in syndicated form. The firms that commission custom bioinformatics market research now will set the pricing benchmarks the rest of the industry references for the next decade.<\/p>\n

\u062d\u0648\u0644 \u0633\u064a\u0633 \u0627\u0644\u062f\u0648\u0644\u064a\u0629<\/h2>\n

\u0633\u064a\u0633 \u0627\u0644\u062f\u0648\u0644\u064a\u0629<\/a> \u064a\u0642\u062f\u0645 \u0627\u0644\u0628\u062d\u0648\u062b \u0627\u0644\u0643\u0645\u064a\u0629 \u0648\u0627\u0644\u0646\u0648\u0639\u064a\u0629 \u0648\u0627\u0644\u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0629. \u0646\u062d\u0646 \u0646\u0642\u062f\u0645 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0648\u0627\u0644\u0623\u062f\u0648\u0627\u062a \u0648\u0627\u0644\u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0627\u062a \u0648\u0627\u0644\u062a\u0642\u0627\u0631\u064a\u0631 \u0648\u0627\u0644\u0631\u0624\u0649 \u0644\u0627\u062a\u062e\u0627\u0630 \u0627\u0644\u0642\u0631\u0627\u0631. \u0646\u0642\u0648\u0645 \u0623\u064a\u0636\u064b\u0627 \u0628\u0625\u062c\u0631\u0627\u0621 \u0627\u0644\u0645\u0642\u0627\u0628\u0644\u0627\u062a \u0648\u0627\u0644\u062f\u0631\u0627\u0633\u0627\u062a \u0627\u0644\u0627\u0633\u062a\u0642\u0635\u0627\u0626\u064a\u0629 \u0648\u0645\u062c\u0645\u0648\u0639\u0627\u062a \u0627\u0644\u062a\u0631\u0643\u064a\u0632 \u0648\u063a\u064a\u0631\u0647\u0627 \u0645\u0646 \u0623\u0633\u0627\u0644\u064a\u0628 \u0648\u0623\u0633\u0627\u0644\u064a\u0628 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0648\u0642. \u0627\u062a\u0635\u0644 \u0628\u0646\u0627<\/a> \u0644\u0645\u0634\u0631\u0648\u0639 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0648\u0642 \u0627\u0644\u0642\u0627\u062f\u0645.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n